Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: Coexpression with VEGFR-3 and PDGF-b predicts poor survival

Journal of Thoracic Oncology

Volumn 4, Issue 5, 2009, Pages 578-585

  Donnem, Tom ^a,b   Al Shibli, Khalid ^a,c   Al Saad, Samer ^a,b   Busund, Lill Tove ^a,b   Bremnes, Roy M ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

Angiogenesis; B FGF; FGF2; FGFR; NSCLC; Stroma

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PLATELET DERIVED GROWTH FACTOR B; VASCULOTROPIN RECEPTOR 3; FGFR1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL; TUMOR CELL; ADENOCARCINOMA; ENZYME IMMUNOASSAY; LARGE CELL CARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TISSUE MICROARRAY;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RETROSPECTIVE STUDIES; STROMAL CELLS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 67651165437     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31819f2e38     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Flehinger BJ, Kimmel M, Melamed MR. The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest 1992;101:1013-1018.
3. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-11707
4. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005;16:159-178.
5. Berger W, Setinek U, Mohr T, et al. Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 1999;83:415-423. (Pubitemid 29455767)
6. Gualandris A, Rusnati M, Belleri M, et al. Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ 1996;7:147-160. (Pubitemid 26049823)
7. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-158. (Pubitemid 43144358)
8. Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg 2004;25:443-448. (Pubitemid 38340585)
9. Kojima H, Shijubo N, Abe S. Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma. Cancer 2002;94:1083-1093. (Pubitemid 34150864)
10. Shou Y, Hirano T, Gong Y, et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer 2001;85:1706-1712. (Pubitemid 34081517)
11. Takanami I, Tanaka F, Hashizume T, et al. The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markers. Eur J Cancer 1996;32A: 1504-1509. (Pubitemid 26279115)
12. Volm M, Koomagi R, Mattern J, Stammler G. Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur J Cancer 1997;33:691-693. (Pubitemid 27223759)
13. Guddo F, Fontanini G, Reina C, Vignola AM, Angeletti A, Bonsignore G. The expression of basic fibroblast growth factor (bFGF) in tumorassociated stromal cells and vessels is inversely correlated with nonsmall cell lung cancer progression. Hum Pathol 1999;30:788-794. (Pubitemid 29325785)
14. Brattstrom D, Bergqvist M, Larsson A, et al. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 1998;18:1123-1127. (Pubitemid 28239651)
15. Brattstrom D, Bergqvist M, Hesselius P, et al. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer 2002;37:57-63. (Pubitemid 34621459)
16. Brattstrom D, Bergqvist M, Hesselius P, Larsson A, Wagenius G, Brodin O. Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer 2004;43: 55-62. (Pubitemid 38096292)
17. Joensuu H, Anttonen A, Eriksson M, et al. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 2002;62:5210-5217. (Pubitemid 35024592)
18. Ueno K, Inoue Y, Kawaguchi T, Hosoe S, Kawahara M. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 2001;31: 213-219. (Pubitemid 32107018)
19. Arbiser JL. Why targeted therapy hasn't worked in advanced cancer. J Clin Invest 2007;117:2762-2765.
20. Nissen LJ, Cao R, Hedlund EM, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007;117:2766-2777. (Pubitemid 47529608)
21. Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y, Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A 2002;99:8868-8873. (Pubitemid 34693650)
22. Donnem T, Al-Saad S, Al-Shibli K, et al. Inverse Prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res 2007;13:6649-6657. (Pubitemid 350206800)
23. Donnem T, Al-Shibli K, Al-Saad S, Delghandi MP, Busund LT, Bremnes RM. VEGF-A and VEGFR-3 correlate with nodal status in operable non-small cell lung cancer: inverse correlation between expression in tumor and stromal cells. Lung Cancer 2009;63:277-283.
24. Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Busund LT, Bremnes RM. Prognostic impact of platelet-derived growth factors in NSCLC tumor and stromal cells. J Thorac Oncol 2008;3:963-970.
25. World Health Organization. Histological Typing of Lung and Pleural Tumours, 3 Ed. Geneva, Switzerland: Springer-Verlag, 1999.
26. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6: 24-37. (Pubitemid 43053650)
27. Al-Shibli K, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic impact of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008;15:5220-5227.
28. Saaristo A, Karpanen T, Alitalo K. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 2000;19:6122-6129. (Pubitemid 32059462)
29. Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999; 154:1381-1390. (Pubitemid 29226433)
30. Chang L, Kaipainen A, Folkman J. Lymphangiogenesis new mechanisms. Ann N Y Acad Sci 2002;979:111-119.
31. Chang LK, Garcia-Cardena G, Farnebo F, et al. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A 2004;101:11658-11663. (Pubitemid 39095352)
32. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005;438:946-953. (Pubitemid 43093960)